自胰高血糖素样肽1(glucagon-like pe ptide-1,GLP-1)发现以来,国内外研究焦点主要集中在降糖疗效上。糖尿病主要并发症是动脉粥样硬化(athero-sclerosis,As),GLP-1对As及其心血管风险是否有防治作用受到高度关注[1-2]。As病变触发于内膜,伴有血管平滑肌细胞(vascular smooth muscle cell,VSMC)的增生迁移和免疫细胞浸润[3],之后出现局部 Since the discovery of glucagon-like peptide-1 (GLP-1), the research focus at home and abroad mainly focuses on the therapeutic effect of hypoglycemic. The main complication of diabetes is athero-sclerosis (As), and whether or not GLP-1 has a preventive and therapeutic effect on As and its cardiovascular risk is of great concern [1-2]. As disease triggers in the intima with hyperplastic migration and immune cell infiltration of vascular smooth muscle cells (VSMCs) [3], followed by localized